CSF2 and Sepsis: Our meta-analysis, which included 12 relevant RCTs comparing G-CSF or GM-CSF with placebo, demonstrated that G-CSF or GM-CSF therapy did not significantly reduce all cause mortality at 14 days or 28 days or in-hospital mortality in patients with sepsis.